MAPT and Alzheimer disease: Another orally bioavailable MMBO molecule (2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole) produced similar results in that it suppressed tau pathology and improved cognitive and memory deficits in 3xTg-AD mice (Onishi et al., 2011).